text.skipToContent text.skipToNavigation

Maximum quantity allowed is 999

Please select the quantity

CAS RN: 129-06-6 | Product Number: W0005

Warfarin Sodium (contains Isopropyl Alcohol)

Purity: >98.0%(HPLC)
  • 3-(α-Acetonylbenzyl)-4-hydroxycoumarin Sodiuim Salt (contains Isopropyl Alcohol)
  • 4-Hydroxy-3-(3-oxo-1-phenylbutyl)coumarin Sodium Salt (contains Isopropyl Alcohol)
≥20  7   11  
8   2   Contact Us
Available Stock: Prompt shipment (for products) in Saitama/Hyogo warehouse. Stock in other WH: 2-3 Business Days
* Please contact us if you need further information.
* To send your quote request for bulk quantities, please click on the "Request Bulk Quote" button. Please note that we cannot offer bulk quantities for some products.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.

Product Number W0005
Purity / Analysis Method >98.0%(HPLC)
Molecular Formula / Molecular Weight C__1__9H__1__5NaO__4 = 330.31  
Physical State (20 deg.C) Solid
Store Under Inert Gas Store under inert gas
Condition to Avoid Air Sensitive
CAS RN 129-06-6
Related CAS RN 81-81-2
Reaxys Registry Number 5469050
PubChem Substance ID 87560363
Merck Index (14) 10038
MDL Number


Appearance White to Almost white powder to crystal
Purity(HPLC) min. 98.0 area%
Purity(Nonaqueous Titration) min. 91.0 %
2-Propanol 7.0 to 9.0 %
Properties (reference)
Solubility in water Completely soluble
Solubility (very soluble in) Alcohol
Solubility (slightly sol. in) Ether,Chloroform
Pictogram Pictogram Pictogram
Signal Word Danger
Hazard Statements H300 : Fatal if swallowed.
H360 : May damage fertility or the unborn child.
H370 : Causes damage to organs.
H372 : Causes damage to organs through prolonged or repeated exposure.
H373 : May cause damage to organs through prolonged or repeated exposure.
H412 : Harmful to aquatic life with long lasting effects.
Precautionary Statements P501 : Dispose of contents/ container to an approved waste disposal plant.
P273 : Avoid release to the environment.
P260 : Do not breathe dust/ fume/ gas/ mist/ vapors/ spray.
P270 : Do not eat, drink or smoke when using this product.
P202 : Do not handle until all safety precautions have been read and understood.
P201 : Obtain special instructions before use.
P264 : Wash skin thoroughly after handling.
P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection.
P308 + P311 : IF exposed or concerned: Call a POISON CENTER/doctor.
P301 + P310 + P330 : IF SWALLOWED: Immediately call a POISON CENTER/doctor. Rinse mouth.
P405 : Store locked up.
Related Laws:
ISHL Organic Solvents Class 2
RTECS# GN4725000
Transport Information:
UN Number UN1544
Class 6.1
Packing Group II
Warfarin Sodium (contains Isopropyl Alcohol) Binding of Warfarin to Human Serum Albumin

Warfarin is known to have affinity for Human Serum Albumin (HSA) and to bind (interact) to drug binding site I on HSA. Those were confirmed using our warfarin sodium with Surface Plasmon Resonance (SPR) and a method using fluorescent probes. 【SPR】Dose responses of warfarin to HSA were confirmed by SPR. Biacore, as a SPR biosensor, was used for the assay, according to the user’s guide of the instrument.


Fluorescent Dye Cocktail for Multiplex Drug¬Site Mapping on Human Serum Albumin

J. C. Er, M. Vendrell, M. K. Tang, D. Zhai, Y. T. Chang, ACS Comb. Sci. 2013, 15, 452.

High-resolution and high-throughput protocols for measuring drug/human serum albumin interactions using BIACORE

R. L. Rich, Y. S. Day, T. A. Morton , D. G. Myszka, Anal Biochem. 2001, 296, 197.

Biosensor Analysis of the Interaction between Immobilized Human Serum Albumin and Drug Compounds for Prediction of Human Serum Albumin Binding Levels

Å. Frostell-Karlsson, A. Remaeus, H. Roos, K. Andersson, P. Borg, M. Hämäläinen, R. Karlsson, J. Med. Chem. 2000, 43, 1986.

Characterizing a drug's primary binding site on albumin

Y. S. Day, D. G. Myszka, J. Pharm. Sci. 2003, 92, 333.

Structural basis of the drug-binding specificity of human serum albumin

J. Ghuman, P. A. Zunszain,I. Petitpas, A. A. Bhattacharya, M. Otagiri, S. Curry, J. Mol. Biol. 2005, 353, 38.

Reviews of Pharmacology of Warfarin

Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol

M. Ufer, Clin. Pharmacokinet. 2005, 44, 1227.

Systematic overview of warfarin and its drug and food interactions

A. M. Holbrook, J. A. Pereira, R. Labiris, H. McDonald, J. D. Douketis, M. Crowther, P. S. Wells, Arch. Intern. Med. 2005, 165, 1095.

Pharmacogenetics of warfarin elimination and its clinical implications

H. Takahashi, H. Echizen, Clin. Pharmacokinet. 2001, 40, 587.

Pharmacogenetics of warfarin: current status and future challenges

M. Wadelius, M. Pirmohamed, Pharmacogenomics J. 2007, 7, 99.

Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues

B. F. Gage, L. J. Lesko, J. Thromb. Thrombolysis. 2008, 25, 45.

Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.

The requested SDS is not available.

Please Contact Us for more information.

C of A & Other Certificates
Please enter Lot Number Incorrect Lot Number is entered
Analytical Charts
Please enter Lot Number Incorrect Lot Number is entered

The requested analytical chart is not available. Sorry for the inconvenience.

Other Documents